Advertisement

Monoclonal Antibodies to Adhesion Molecules in Bone Marrow and Organ Transplantation

  • Alain Fischer
  • M. Cavazzana-Calvo
  • N. Jabado
  • S. Sarnacki
Part of the Medical Intelligence Unit book series (MIU.LANDES)

Abstract

A number of adhesion molecules have been characterized in the recent past. Molecules belonging to three families, i.e. selectins, integrins and members of the immunoglobulin superfamily mediate major events of immune reactions.1,2 These events include migration of naïve cells to lymphoid organs (homing), adhesion of T cells to antigen-presenting cells, adhesion between effector helper or cytotoxic T cells and B cells or target cells respectively, migration of lymphocytes (as well as monocytes and granulocytes) from the blood stream to sites of immune reaction. T-cell activation and migration are obvious key phenomena in the process of graft rejection and graft versus host disease (GVHD). Adhesion molecules therefore represent logical targets for immunointervention aim at preventing graft rejection. In this chapter, we review the current experimental and clinical data on the in vivo use of anti-adhesion molecule antibodies in the field of transplantation.

Keywords

Graft Rejection Leukocyte Adhesion Deficiency Corneal Allograft Engraftment Rate Prevent Graft Rejection 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Springer TA. Adhesion receptors of the immune system. Nature 1990; 346: 425–434.PubMedCrossRefGoogle Scholar
  2. 2.
    Hyners RO. Integrins: versatility, modulation and signaling in cell adhesion. Cell 1992; 69: 11–25.CrossRefGoogle Scholar
  3. 3.
    Diamond MS, Springer TA. The dynamic regulation of integrin adhesiveness. Current Biol 1994; 4: 506–517.CrossRefGoogle Scholar
  4. 4.
    Amblard F, Auffray C, Sekaly R et al. Molecular analysis of antigen-independent adhesion forces between T and B lymphocytes. PNAS 1994; 91: 3628–3632.PubMedCrossRefGoogle Scholar
  5. 5.
    Fischer A. Anti-LFA-1 antibody as immunosuppressive reagent in transplantation. Chem Immunol 1991; 50: 89–97.PubMedCrossRefGoogle Scholar
  6. 6a.
    Landis RC, McDowall A, Holness CLL et al. Involvement of the “I” domain of LFA-1 in selective binding to ligands ICAM-1 to ligands ICAM-1 and ICAM-3. J Cell Biol 1994; 126: 529–537.PubMedCrossRefGoogle Scholar
  7. 6b.
    Stanley P, Bastes PA, Harvey JA et al. Integrin LFA-1 a subunit contains an ICAM-1 binding site in domains V and VI. Embo J 1994; 13: 1790–1798.PubMedGoogle Scholar
  8. 7.
    Dustin Ml, Springer TA. T-cell receptor cross-linking transiently stimulates adhesiveness through LFA-1. Nature 1989; 341: 619–621.PubMedCrossRefGoogle Scholar
  9. 8.
    Van Kooyk Y, Van De Wiel-Van Kemenade E, Weder P et al. Enhancement of LFA-1-mediated cell adhesion by triggering through CD2 or CD3 on T-lymphocytes. Nature 1989; 342: 811–13.PubMedCrossRefGoogle Scholar
  10. 9.
    Arroyo AG, Campanero MR, Sanchez-Mateos P et al. Induction of tyrosine phosphorylation during ICAM-3 and LFA-1 mediated intercellular adhesion and its regulation by the CD45 tyrosine phosphatase. J Cell Biol 1994; 126: 1277–1286.PubMedCrossRefGoogle Scholar
  11. 10.
    Van Seventer GA, Shimizu Y, Horgan KJ et al. The LFA-1 ligand ICAM-1 provides an important costimulary signal for T-cell receptor-mediated activation of resting T-cells. J Immunol 1990; 144: 4579–4583.PubMedGoogle Scholar
  12. 11.
    Figdor CG, Van Kooyk Y, Keizer GD. On the mode of action of LFA-1. Immunol Today 1950; 11: 277–279.CrossRefGoogle Scholar
  13. 12.
    Fischer A, Lisowska-Grospierre B, Anderson DC et al. The leukocyte adhesion deficiency. Immunodef Rev 1988; 2: 39–54.Google Scholar
  14. 13.
    Le Deist F, Blanche S, Keable H et al. Successful HLA-non identical bone marrow transplantation in three patients with leukocyte adhesion deficiency. Blood 1989; 74: 512–517.PubMedGoogle Scholar
  15. 14.
    Thomas C, Le Deist F, Friedrich W et al. Bone marrow transplantation for the treatment of children with leukocyte adhesion deficiency. A revue of 14 cases. Submitted.Google Scholar
  16. 15.
    Kohl S, Loo Ls, Schmalstieg FS et al. The genetic deficiency of leukocyte surface glycoproteins Mac-1, LFA-1, p150,95 in humans is associated with defective antibody-dependent cellular cytotoxicity and defective protection against herpes simplex virus infection in vivo. J Immunol 1986; 177: 1688–1693.Google Scholar
  17. 16.
    Muller KE, Rutten UPMG, Becker CK et al. Skin transplantations in β2-integrin deficient cattle.Google Scholar
  18. 17.
    Wilson RW, Ballatyne CM, Smith CW et al. Gene targeting yields a CD18-mutant mouse for study of inflammation. J Immunol 1993; 151: 1571–1578.PubMedGoogle Scholar
  19. 18.
    Makgoba MW, Sangers ME, Shaw S. The CD2/LFA-3 and LFA-1/ICAM pathways: relevance to T-cell recognition. Immunol Today 1989; 10: 417–420.PubMedCrossRefGoogle Scholar
  20. 19.
    Krensky AM, Sanchez-Madrid F, Robbins E et al. The functional significance, distribution and structure of LFA-1, LFA-2 and LFA-3: cell surface antigens associated with CTL-target interactions. J Immunol 1983; 131: 611–617.PubMedGoogle Scholar
  21. 20.
    Mentzer SJ, Krensky AM, Burakoff SJ. Mapping functional epitopes of the human LFA-1 glycoprotein: monoclonal antibody inhibition of NK and CTL effectors. Hum Immunol 1986; 17: 288–295.PubMedCrossRefGoogle Scholar
  22. 21.
    Mazerolles F, Lumbroso C, Lecomte O et al. The role of LFA-1 in the adherence of T-lymphocytes to B-lymphocytes. Eur J Immunol 1988; 18: 1229–1234.PubMedCrossRefGoogle Scholar
  23. 22.
    Heagy W, Waltenbaugh C. Potent ability of anti-LFA-1 monoclonal antibody to prolong allograft survival. Transplantation 1984; 37: 520–523.PubMedCrossRefGoogle Scholar
  24. 23.
    Van Dijken PJ, Ghayur T, Mauch P et al. Evidence that anti-LFA-1 in vivo improves engraftment and survival after allogeneic bone marrow transplantation. Transplantation 1990; 49: 882–886.PubMedCrossRefGoogle Scholar
  25. 24.
    Cavazzaana-Calvo M, Sarnacki S, Haddad E et al. Prevention of bone marrow and cardiac graft rejection in an H-2 haplotype disparate mouse combination by an anti-LFA-1 antibody. Submitted.Google Scholar
  26. 25.
    Harning R, Pelletier J, Lubbe K et al. Reduction in the severity of graft-versus host disease and increased survival in allogeneic mice by treatment with monoclonal antibodies to cell adhesion antigens LFA-1a and MALA-2. Transplantation 1991; 52: 842–845.PubMedCrossRefGoogle Scholar
  27. 26.
    Isobe M, Yagita H, Okumura K et al. Specific acceptance of cardiac allograft after treatment with antibodies to ICAM-1 and LFA-1. Science 1992; 255: 1125–1127.PubMedCrossRefGoogle Scholar
  28. 27.
    Nakakura EK, McCabe SM, Zheng B et al. Potent and effective prolongation by anti-LFA-1 monoclonal antibody monotherapy of non-primarily vascularized heart allograft survival in mice without T-cell depletion. Transplantation 1993; 55: 412–417.PubMedGoogle Scholar
  29. 28.
    Kameoka H, Ishibashi M, Tamantani T et al. The immunosuppressive action of anti-CD 18 monoclonal antibody in rat heterotopic heart allotransplantation. Transplantation 1993; 55: 665–667.PubMedGoogle Scholar
  30. 29.
    Paul LC, Davidoff A, Benediktsson M et al. The efficacy of LFA-1 and VLA-4 antibody treatment in rat vascularized cardiac allograft rejection. Transplantation 1993; 55: 1196–1199.PubMedCrossRefGoogle Scholar
  31. 30.
    Pelletier R, Ohye R, Kincade P et al. Monoclonal antibody to anti-VCAM-1 interferes with murine cardiac allograft rejection. Transplant Proc 1993; 25: 839–841.PubMedGoogle Scholar
  32. 31.
    Qin L, Chavin KD, Lin J et al. Anti-CD2 receptor and anti-CD2 ligand (CD48) antibodies synergize to prolong allograft survival. J Exp Med 1994; 179: 341–346.PubMedCrossRefGoogle Scholar
  33. 32.
    Gückel B, Berek C, Lutz M, Altevogt P et al. Anti-CD2 antibodies induce T-cell unresponsiveness in vivo. J Exp Med 1991; 174: 957–967.PubMedCrossRefGoogle Scholar
  34. 33.
    Chavin K, Qin L, Woodward JE et al. Anti-CD2 monoclonal antibodies synergize with FK506 but not with cyclosporine or rapamycin to induce tolerance. Transplantation 1994; 57: 736–740.PubMedCrossRefGoogle Scholar
  35. 34.
    Jendrisak M, Jendrisak G, Gamero J et al. Prolongation in murine cardiac survival with monoclonal antibodies to LFA-1, ICAM-1 and CD4. Transplant Proc 1993; 25: 825–827.PubMedGoogle Scholar
  36. 35.
    Gotoh M, Fukuzaki T, Mondren M et al. A potential immunosuppressive effect of anti-lymphocyte function-associated antigen-1 monoclonal antibody on islet transplantation. Transplantation 1994; 57: 123–126.PubMedGoogle Scholar
  37. 36.
    He YG, Mellon J, Apte R et al. Effect of LFA-1 and ICAM-1 antibody treatment on murine corneal allograft survival. Invest Ophtalmol Vis Sci 1994; 35: 3218–3225Google Scholar
  38. 37.
    Grooby WL, Carter JK, Rao MM et al. Use of an anti-LFA-1 antibody in renal allograft rejection in sheep. Transplant Proc 1992; 24: 2304.PubMedGoogle Scholar
  39. 38.
    Cosimi AB, Conti D, Delmonico FL et al. In vivo effects of monoclonal antibody to ICAM-1 (CD54) in non human primates with renal allografts. J Immunol 1990; 144: 4604–4612.PubMedGoogle Scholar
  40. 39.
    Flavin T, Ivens K, Faanes R et al. Monoclonal antibodies against IC AM-1 prolony cardic allograft survival in cynomolgus monkeys. Transplant Proc 1991; 23: 533–534.PubMedGoogle Scholar
  41. 40.
    Berlin PJ, Bacher JD, Sharrow SO et al. Monoclonal antibodies against human T-cell adhesion molecules—modulation of immune function in non human primates. Transplantation 1992; 53: 840–849.PubMedCrossRefGoogle Scholar
  42. 41.
    Fischer A, Blanche S, Veber F et al. Prevention of graft failure by an anti-LFA-1 monoclonal antibody in HLA mismatched bone marrow transplantation. Lancet 1986; 2: 1068–1071.Google Scholar
  43. 42.
    Perez N, Le Deist F, Chatenoud L et al. In vivo infusions of anti-LFA-1 antibody in HLA non identical and biological effects. Bone Marrow Transplant 1989; 4: 379–385.PubMedGoogle Scholar
  44. 43.
    Fischer A, Friedrich W, Fasth A et al. Reduction of graft failure by a monoclonal antibody (anti-LFA-1, CD11a) after HLA-non identical bone marrow transplantation in children with immunodeficiencies, osteopetrosis and Fanconi’s anemia. Blood 1991; 2: 249–256.Google Scholar
  45. 44.
    Jabado N, Le Deist F, De Graaf Meiders B et al. Combined use of two monoclonal antibodies (anti-LFA-1 and anti-CD2) to prevent graft rejection in recipients of T-depleted marrow from genetically HLA-non identical donors in children with inherited disorders. Submitted.Google Scholar
  46. 45.
    Cavazzana-Calvo M, Bordigoni P, Michel G, Baruchel A et al. Partially incompatible marrow transplantation therapy for high risk acute lymphoblastic leukemia in children: Analysis of prevention of graft rejection by anti-LFA-1 and anti-CD2 antibodies. A SFGM study. Submitted.Google Scholar
  47. 46.
    Baume D, Kuentz M, Pico JL et al. Failure of a CD18/anti-LFA-l monoclonal antibody infusion to prevent graft rejection in leukemic patients receiving T-depleted allogeneic bone marrow transplantation. Transplantation 1989; 47: 472–474.PubMedCrossRefGoogle Scholar
  48. 47.
    Marawinchi D, Mawas C, Stoppa AM et al. Anti-LFA-1 monoclonal antibody for the prevention of graft rejection after T-cell depleted HLA-matched bone marrow transplantation for leukemia in adults. Bone Marrow Transplant 1989; 4: 147.Google Scholar
  49. 48.
    Ohashi Y, Tsuchiya S, Fujie H et al. Anti-LFA-1 antibody treatment of a patient with steroid-resistant severe graft-versus-host disease. Tohoku J Exp Med 1992; 167: 297–299.PubMedCrossRefGoogle Scholar
  50. 49.
    Le Mauff B, Hourmant M, Rougier JP et al. Effect of anti-LFA-1 (CD11a) monoclonal antibodies in acute rejection in human kidney transplantation. Transplantation 1991; 52: 291–296.PubMedCrossRefGoogle Scholar
  51. 50.
    Hourmant M. Le Mauff B, Le Meur Y et al. Administration of an anti-CD11a monoclonal antibody in recipients of kidney transplantation. A pilot study. Transplantation 1994; 58: 377–380.PubMedGoogle Scholar
  52. 51.
    Haugg CE, Colvin RB, Delmonico FL et al. A phase I trial of immunosuppression with ICAM-1 (CD54) MoAb in renal allograft recipients. Transplantation 1993; 55: 766–773.CrossRefGoogle Scholar
  53. 52.
    Benjamin RJ, Qui S, Wise MP et al. Mechanisms of monoclonal antibody-facilitated tolerance induction: a possible role for the CD4 (L3T4) and CD11a (LFA-1) molecules in self-non-self discrimination. Eur J Immunol 1988; 18: 1079–84.PubMedCrossRefGoogle Scholar
  54. 53.
    Schwartz RH. A cell culture model for T lymphocyte clonal anergy. Science 1990; 248: 1349–1356.PubMedCrossRefGoogle Scholar
  55. 54.
    Wallace PM, Johnson JS, MacMaster JF et al. CTLA4 Ig treatment ameliorates the lethality of murine graft-versus-host disease across major histocompatibility complex barriers. Transplantation 1994; 58: 602–610.PubMedCrossRefGoogle Scholar
  56. 55.
    Janeway CA, Carding S, Jones B et al. CD4+ T-cells: specificity and function. Immunol Rev 1988; 101: 39–80.PubMedCrossRefGoogle Scholar
  57. 56.
    Chavin KD, Qin L, Yon R et al. Anti-CD2 MoAbs suppress cytotoxic lymphocytic activity by the generation of Th2 suppressor cells and receptor blockade. J Immunol 1994; 152: 3729–3739.PubMedGoogle Scholar
  58. 57.
    Ohno H, Nakamura T, Yagita H et al. Induction of negative signal through CD2 during antigen-specific T-cell activation. J Immunol 1991; 147: 2100–2106.PubMedGoogle Scholar
  59. 58.
    Qin S, Cobbold SP, Pope H et al. “Infectious tolerance” transplantation tolerance. Science 1993; 259: 974–977.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1995

Authors and Affiliations

  • Alain Fischer
  • M. Cavazzana-Calvo
  • N. Jabado
  • S. Sarnacki

There are no affiliations available

Personalised recommendations